MS and Demyelinating Disorders

The clinical research coordinator at Massachusetts General Hospital discussed his presentation from ACTRIMS 2021 on electronic pill bottle monitoring to promote MS medication adherence.

The chair of the Department of Neurology and the director of the Neuroscience Research Institute at The Ohio State University discussed his lecture at ACTRIMS Forum 2021.

June Halper, chief executive officer of the Consortium of Multiple Sclerosis Centers, provides an inside perspective on MS education during MS Awareness Month.

The assistant professor of neurology at Mayo Clinic provided his thoughts on the next steps in understanding autoimmune encephalitis and the direction that research must pivot to.

The authors expanded upon the notion that nonadherence to oral DMTs is more nuanced than simply missing doses.

The researchers found that interleukin-1 receptor antagonist levels in plasma correlated with neurofilament light levels in cerebrospinal fluid.

Researchers found that 22 of 23 patients with elevated CSF NfL at baseline had normal levels at 2-year follow-up.

The chief medical officer at Clene Nanomedicine discussed the recently presented data on CNM-Au8 from the VISIONARY-MS trial.

The authors noted that future studies evaluating the time course of fatigue in patients with multiple sclerosis are needed.

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed areas of multiple sclerosis research that need more attention.

Here's what is coming soon to NeurologyLive.

The assistant professor of neurology at Mayo Clinic detailed his presentation at ACTRIMS 2021 Forum on the rising prevalence of autoimmune encephalitis.

Clene Nanomedicine’s nanocatalyst agent CNM-Au8 displayed significant improvements in patients with EDSS scores of 2.0 or higher compared to those with EDSS scores of 1.5 or lower.

The neurologist from Massachusetts General Hospital gave an overview of her study presented at ACTRIMS.

Researchers from Massachusetts General Hospital found that DMT-treated patients were, on average, younger than untreated patients.

Higher concealment behavior for patients with multiple sclerosis was associated with higher anxiety, but not depression.

The global head of medical affairs-neurology at Janssen Pharmaceutical provided background on the need for real-world studies and how they can accurately portray a disease community.

The authors concluded that longitudinal optical coherence tomography measures may be sensitive to changes in cognitive function and may be useful for monitoring neuroprotective therapies.

Neurology News Network for the week ending February 27, 2021.

Researchers from the University of Washington Medical Center analyzed data from almost 10,000 infusions of natalizumab.

Data from a pair of posters suggest that cognition, fatigue, and depression all impact social activity limitations in people with MS, rather than walking impairment alone.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 26, 2021.

Researchers investigated the test, which is normally used to differentiate people with MS from healthy controls, in a population of those with multiple sclerosis.

The fellow of autoimmune neurology at Massachusetts General Hospital discussed the analysis his team conducted to clarify the known associations.

The trial of anakinra is underway, while the trial for tolebrutinib is undergoing regulatory review.